SAN DIEGO – The editors of Nature Biotechnology recently published an editorial entitled “Ultra-precision medicine” in the June 2021 issue of Nature Biotechnology[i], highlighting new initiatives in n-of-1 drug development, as well as the rapid progress that n-Lorem Foundation, a nonprofit organization providing the ultra-rare disease community with free, lifetime supplies...
Latest News
TORONTO, Canada – Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the publication in Nature Communications of new research from a scientific team at the Ottawa Hospital Research Institute (OHRI) that validates the company’s novel...
NAARDEN, Netherlands, WALTHAM, Mass. & BARCELONA, Spain — Prilenia Therapeutics B.V. and Ferrer today announced the publication, in the journal Nature Medicine, of a manuscript entitled “Pridopidine in Early-Stage Manifest Huntington Disease: A Phase 3 Trial“ii. The publication describes data showing that treatment with pridopidine slowed clinical progression in Huntington’s disease (HD)...
CHENGDU, China — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech”, HKEX: 6990) announced that clinical data from a Phase II study evaluating novel TROP2 antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) in combination with PD-L1 monoclonal antibody (mAb) tagitanlimab for the first-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) have been...
LAS VEGAS — Bone sarcoma is a rare and aggressive form of cancer that originates in the bone tissue. It poses significant challenges during its treatment due to several factors. Firstly, its rarity often leads to delayed diagnosis, as symptoms can mimic other common conditions. Additionally, bone sarcoma typically affects...
Bethesda, Maryland – Researchers have shown that dangerous cysts, which form over time in polycystic kidney disease (PKD), can be prevented by a single normal copy of a defective gene. This means the potential exists that scientists could one day tailor a gene therapy to treat the disease. They also...
NEW YORK, NY — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia were updated to include revumenib as a category 2A recommendation for relapsed or refractory (R/R)...
PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network® (NCCN®) is announcing several new updates to the cancer treatment practices listed in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). The evidence-based expert consensus recommendations are the most frequently updated guidelines for any area of medicine and are used...
Boston, Mass. – An important discovery from the NCI-MATCH precision medicine initiative is being published today in Clinical Cancer Research, a journal of the American Association for Cancer Research. Trastuzumab-pertuzumab, a drug combination approved by the US Food and Drug Administration (FDA) to treat patients with human epidermal growth factor...
CHICAGO — Most patients with Type 2 diabetes will end up needing to add a second-line medication after metformin — the go-to primary drug for glucose management — to control their blood sugar levels. But adherence to these second-line drugs can be hit or miss, reports a new Northwestern Medicine...